<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce S Bochner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia [
         <a href="#rid1">
          1-8
         </a>
         ]. EGPA is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease.
        </p>
        <p>
         The most commonly involved organ is the lung, followed by the skin. EGPA, however, can affect any organ system, including the cardiovascular, gastrointestinal, renal, and central nervous systems. Vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA.
        </p>
        <p>
         The clinical features and diagnosis of EGPA will be reviewed here. The epidemiology, pathogenesis, treatment, and prognosis of this disorder, as well as the approach to patients with vasculitis and/or eosinophilia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">
          "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">
          "Approach to the patient with unexplained eosinophilia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common presenting features of EGPA are asthma, nasal and sinus symptoms, and peripheral neuropathy [
         <a href="#rid6">
          6,8,9
         </a>
         ]. EGPA is a multiorgan system disease and other manifestations that may be present initially or develop over the course of the disease include weight loss, fever, myalgia, arthralgia, skin involvement, pulmonary opacities, cardiomyopathy, kidney disease, and gastrointestinal involvement. The mean age at diagnosis is 50 years [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Phases of disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features of EGPA typically develop in several sequential phases, although these phases are not always clearly distinguishable [
         <a href="#rid10">
          10,11
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prodromal phase – The prodromal phase occurs among individuals in the second and third decades of life and is characterized by atopic disease, allergic rhinitis, and asthma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilic phase – Features of the eosinophilic phase include peripheral blood eosinophilia and eosinophilic infiltration of multiple organs, especially the lung and gastrointestinal tract. Almost 40 percent of patients with EGPA present with pulmonary opacities, asthma, and peripheral eosinophilia prior to the development of a systemic vasculitis (polyangiitis) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasculitic phase – The vasculitic phase is characterized by a life-threatening systemic vasculitis of the medium and small vessels frequently occurs, that is often associated with vascular and extravascular granulomatosis [
         <a href="#rid6">
          6
         </a>
         ]. The vasculitic phase may be heralded by nonspecific constitutional symptoms and signs, especially fever, weight loss, malaise, and lassitude.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Asthma and lung disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Asthma is the cardinal clinical feature of EGPA and is present in more than 90 percent of patients [
         <a href="#rid8">
          8,9
         </a>
         ]. Asthma usually precedes the vasculitic phase by approximately 8 to 10 years [
         <a href="#rid6">
          6,12
         </a>
         ]. (See
         <a class="local">
          'Phases of disease'
         </a>
         above.)
        </p>
        <p>
         EGPA is typically suspected in patients whose asthma is poorly controlled on moderate doses of inhaled glucocorticoids; many patients diagnosed with EGPA require frequent or long-term courses of systemic glucocorticoids to control their asthma [
         <a href="#rid13">
          13
         </a>
         ]. As the vasculitic phase begins, asthma severity and the number of exacerbations may increase. Rarely, the asthma symptoms lessen in the early stages of the vasculitic phase.
        </p>
        <p>
         Prolonged treatment of asthma with glucocorticoid therapy may partially or totally suppress the usual clinical signs of untreated EGPA. The disease may therefore not become evident until glucocorticoids are reduced or stopped [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p>
         Other pulmonary findings are reported in 50 to 70 percent and include pulmonary opacities with eosinophilia, pleural effusion (often eosinophilic), and nodules that are rarely cavitary [
         <a href="#rid3">
          3
         </a>
         ]. Alveolar hemorrhage is rare and usually associated with antineutrophil cytoplasmic antibody (ANCA) positivity [
         <a href="#rid16">
          16
         </a>
         ]. In one series, venous thromboembolic disease was noted in 8 percent [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Upper airway and ear disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ear, nose, and throat involvement, including serous otitis media, allergic rhinitis, nasal obstruction, recurrent sinusitis, and nasal polyposis, is reported in 70 to 85 percent patients with EGPA [
         <a href="#rid8">
          8,17-21
         </a>
         ]. Common presenting symptoms include nasal discharge (88 percent), nasal congestion (84 percent), and/or facial pain or pressure (84 percent) [
         <a href="#rid22">
          22
         </a>
         ]. In a series of 29 patients with EGPA, nasal polyposis was detected in 60 percent [
         <a href="#rid18">
          18
         </a>
         ]. Prior to the onset of eosinophilic infiltration of the lung or other organs, the characteristics of these patients overlap considerably with those associated with aspirin-exacerbated respiratory disease. (See
         <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">
          "Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis", section on 'CRS with nasal polyposis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/520.html" rel="external">
          "Aspirin-exacerbated respiratory disease"
         </a>
         .)
        </p>
        <p>
         Chronic serous otitis media and sensorineural hearing loss are occasionally seen in EGPA and likely reflect the severity of rhinosinusitis [
         <a href="#rid19">
          19,23,24
         </a>
         ]. Necrotizing lesions of the nasopharynx and upper airway are more characteristic of granulomatosis with polyangiitis (GPA), and are unusual in EGPA. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Skin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin involvement is one of the most common features of the vasculitic phase of EGPA. Half to two-thirds of patients with EGPA have skin lesions, which usually appear as tender subcutaneous nodules on the extensor surfaces of the arm, particularly the elbows, hands, and legs  (
         <a class="graphic graphic_picture graphicRef52628" href="/z/d/graphic/52628.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid3">
          3,25-27
         </a>
         ]. Biopsy of these lesions usually reveals granulomas. The pathology of cutaneous EGPA is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
         Skin lesions can also appear as a macular or papular erythematous rash or hemorrhagic lesions, including petechiae, palpable purpura, and extensive ecchymosis [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Cardiovascular
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA [
         <a href="#rid29">
          29,30
         </a>
         ]. Clinical manifestations include clinical signs of heart failure or pericarditis and cardiac rhythm abnormalities [
         <a href="#rid29">
          29,31-33
         </a>
         ]. Patients with cardiac involvement typically have a shorter duration of EGPA related symptoms than those without. Cardiac involvement is more frequent in patients with higher eosinophil counts at the time of diagnosis [
         <a href="#rid29">
          29,34
         </a>
         ].
        </p>
        <p>
         In a series of 383 patients with EGPA, 16 percent had a cardiomyopathy and 15 percent had pericarditis [
         <a href="#rid8">
          8
         </a>
         ]. In a separate series of 22 patients with evidence of cardiac involvement, cardiac abnormalities included an abnormal electrocardiogram (ECG) in all patients; valvular insufficiency, pericardial effusion, and heart failure were noted in 73, 50, and 41 percent, respectively [
         <a href="#rid29">
          29
         </a>
         ]. Endomyocardial involvement was found in 12 patients based on cardiac magnetic resonance imaging (MRI) findings of mural thrombus and a positive endomyocardial biopsy [
         <a href="#rid29">
          29
         </a>
         ]. The majority of patients improved with treatment, although two of the patients with endomyocardial disease died of heart failure. Patients with cardiac involvement were less likely to have a positive antineutrophil cytoplasmic antibody (ANCA) and more likely to have higher peripheral blood eosinophil counts than other EGPA patients.
        </p>
        <p>
         The use of various cardiovascular tests to evaluate myocardial EGPA and the typical biopsy findings seen on endomyocardial biopsy are discussed separately. (See
         <a class="local">
          'Cardiovascular tests'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H280932879">
         <span class="h2">
          Thromboembolic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with EGPA appear to be at increased risk for venous thromboembolism (VTE), similar to that seen in other systemic vasculitides. In a retrospective study of 232 patients with EGPA, the risk of VTE was 8 percent and did not differ significantly between those who were ANCA positive or not [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Neurologic
         </span>
         <span class="headingEndMark">
          —
         </span>
         A peripheral neuropathy, usually affecting at least two separate nerve areas (multiple mononeuropathy, also called mononeuritis multiplex), is seen in up to 75 percent of patients with EGPA and presents with pain, numbness, and/or weakness [
         <a href="#rid3">
          3,6,32,36-41
         </a>
         ]. Untreated, this may progress to a symmetric or asymmetric polyneuropathy [
         <a href="#rid42">
          42
         </a>
         ]. Severe neuropathic pain may accompany the peripheral neuropathy [
         <a href="#rid38">
          38
         </a>
         ]. Patients with mononeuritis multiplex are more likely to have a positive ANCA [
         <a href="#rid9">
          9
         </a>
         ]. A more detailed description of vasculitic neuropathy is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies"
         </a>
         .)
        </p>
        <p>
         In addition, EGPA-related central nervous system manifestations have been reported, including subarachnoid and cerebral hemorrhage, cerebral infarction, cranial nerve palsies, and cortical blindness [
         <a href="#rid6">
          6,41,43-45
         </a>
         ]. Ophthalmic manifestations can include central retinal artery or vein occlusion, ischemic optic neuropathy, conjunctival nodules, and orbital myositis [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Renal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of renal involvement varies among studies [
         <a href="#rid8">
          8,47-49
         </a>
         ]. In the largest series of 383 patients with EGPA, renal involvement was found in 83 patients (22 percent) [
         <a href="#rid8">
          8
         </a>
         ]. Similar findings were noted in a series of 116 patients in which one-half had rapidly progressive or acute renal insufficiency (plasma creatinine concentration &gt;1.4 mg/dL [&gt;124 micromol/L]), while the others had isolated proteinuria or microscopic hematuria [
         <a href="#rid48">
          48
         </a>
         ]. Sixteen patients underwent renal biopsy, which demonstrated necrotizing glomerulonephritis in 11 patients. A positive test for ANCA was found in all patients with glomerulonephritis, compared with 26 percent of patients without renal involvement. (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         below.)
        </p>
        <p>
         Systemic hypertension affects approximately 10 to 30 percent of patients with EGPA and may reflect renal involvement with EGPA or be a complication of glucocorticoid therapy [
         <a href="#rid6">
          6,10,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Gastrointestinal tract
         </span>
         <span class="headingEndMark">
          —
         </span>
         An eosinophilic gastroenteritis, characterized by abdominal pain (59 percent of patients), diarrhea (33 percent), gastrointestinal bleeding (18 percent), and colitis, may precede or coincide with the vasculitic phase of EGPA. (See
         <a class="local">
          'Phases of disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2536.html" rel="external">
          "Eosinophilic gastrointestinal diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Musculoskeletal
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myalgias, migratory polyarthralgias, and frank arthritis are less common, but may affect 40 to 50 percent of patients in the vasculitic phase of the disorder [
         <a href="#rid6">
          6
         </a>
         ]. Although rare, myositis may be a presenting manifestation [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="local">
          'Phases of disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Lymphadenopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Eosinophilic lymphadenopathy has been noted in 30 to 40 percent of patients [
         <a href="#rid15">
          15
         </a>
         ]. Prominent cervical and axillary lymphadenopathy has been reported with individual lymph nodes up to 3 cm in diameter.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         EGPA is typically suspected based on a combination of clinical findings, such as difficult-to-control asthma, chronic rhinosinusitis, and eosinophilia ≥1500/microL. However, confirming the diagnosis is often difficult because of the following confounding factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individual manifestations of the syndrome can occur in isolation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lung parenchymal involvement is not universal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some manifestations can exist for many years before additional features become clinically apparent. (See
         <a class="local">
          'Phases of disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although EGPA is classified as a vasculitis, only 30 to 60 percent of patients with EGPA have antineutrophil cytoplasmic antibodies (ANCA). In addition, many biopsies do not show a necrotizing vasculitis or granuloma, but rather an apparently nondestructive infiltration of vessel walls by eosinophils [
         <a href="#rid52">
          52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no laboratory tests that are specific for EGPA, although eosinophilia is characteristic. For patients who have suspected EGPA, initial testing includes a complete cell count with differential, an absolute eosinophil count, and a serum immunoglobulin E (IgE) level. Eosinophilia, if present, requires further evaluation to determine the cause. In addition, we usually obtain an ANCA test, although the sensitivity and specificity are low, as noted below. (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Eosinophilia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral blood eosinophilia (usually 5000 to 9000 eosinophils/microL) is the most characteristic finding, although absolute eosinophil counts ≥1500 cells/microL (or greater than 10 percent of the total leukocyte count) should prompt suspicion for EGPA [
         <a href="#rid10">
          10,53,54
         </a>
         ]. Eosinophilia, however, is occasionally missed because of rapid spontaneous, or glucocorticoid-induced reductions or fluctuations in eosinophil counts. Tissue eosinophilia can still be found in patients in whom peripheral blood eosinophilia is absent.
        </p>
        <p>
         Patients with an absolute eosinophil count ≥1500 cells/microL should be evaluated for causes of hypereosinophilia other than EGPA  (
         <a class="graphic graphic_table graphicRef76434" href="/z/d/graphic/76434.html" rel="external">
          table 1
         </a>
         ) and for evidence of extrapulmonary involvement with EGPA [
         <a href="#rid55">
          55-59
         </a>
         ] (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum cardiac troponin
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum N-terminal pro-brain natriuretic peptide (NT-proBNP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serology for
         <em>
          Toxocara
         </em>
         ,
         <em>
          Strongyloides
         </em>
         , filaria,
         <em>
          Trichinella
         </em>
         , and other parasites depending on the locale
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoassay for human immunodeficiency virus (HIV) infection
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum vitamin B12
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum tryptase
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral blood smear to identify blasts or dysplastic eosinophils
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis, blood urea nitrogen, serum creatinine
        </p>
        <p>
        </p>
        <p>
         (See
         <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">
          "Approach to the patient with unexplained eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Antineutrophil cytoplasmic antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         ANCA are found in 30 to 60 percent of patients with EGPA [
         <a href="#rid8">
          8,9,12,36,60-62
         </a>
         ]. The majority of ANCA-positive EGPA patients (70 to 75 percent) have antibodies directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA)  (
         <a class="graphic graphic_picture graphicRef78968" href="/z/d/graphic/78968.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid32">
          32,62-65
         </a>
         ]. Antibodies to proteinase-3 (PR3) are unusual in EGPA [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
         EGPA disease manifestations may differ between ANCA-positive and ANCA-negative patients, although confirmatory data are needed [
         <a href="#rid8">
          8,9,11,59,62
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 157 consecutive patients with EGPA, 49 (31 percent) were ANCA positive [
         <a href="#rid9">
          9
         </a>
         ]. ANCA-positivity was associated with weight loss, myalgias, arthralgias, biopsy-proven vasculitis, glomerulonephritis on biopsy, hematuria, leukocytoclastic capillaritis and/or eosinophilic infiltration of the arterial wall on biopsy, and other renal disease. However, 18 percent of those with definite vasculitis were ANCA-negative. Mononeuritis multiplex was associated with systemic vasculitis and ANCA-positivity, although 22 percent of patients with mononeuritis multiplex were ANCA-negative. In terms of ANCA types, 96 percent were specific for myeloperoxidase and 4 percent were specific for PR3.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 383 patients with EGPA, those who were ANCA-positive had clinical vasculitis manifestations, such as peripheral neuropathy or renal involvement, more frequently than ANCA-negative patients, but less frequently had cardiomyopathy [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 112 patients with newly diagnosed EGPA, a positive ANCA at diagnosis was associated with renal involvement, peripheral neuropathy, and biopsy-proven vasculitis, whereas a negative ANCA was associated with heart disease and fever [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A retrospective European multicenter cohort of 734 patients with known ANCA status found that 508 (69.2 percent) were ANCA-negative, 210 (28.6 percent) had positive MPO-ANCA, and 16 (2.2 percent) had positive PR3-ANCA. At baseline, PR3-ANCA positive patients had less frequent active asthma and peripheral neuropathy, more frequent cutaneous manifestations and pulmonary nodules, and lower median eosinophil count compared with those who were MPO-ANCA-positive or ANCA-negative. Vasculitis relapse-free survival was shorter for PR3-ANCA and MPO-ANCA patients compared with ANCA-negative patients [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of 242 Korean patients with EGPA, those who were PR3-ANCA positive at disease diagnosis exhibited peripheral eosinophilia less frequently, experienced relapse more often, and had lower cumulative relapse-free survival rate compared with those without PR3-ANCA [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Acute phase reactants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tests of inflammation such as the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are nonspecific and do not differentiate between flares of EGPA and infections (eg, sinusitis, pneumonia). Their usefulness in EGPA is unclear. (See
         <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">
          "Acute phase reactants", section on 'Clinical use'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Other laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no biomarkers that reliably assess EGPA activity, although CCCL17/TARC, immunoglobulin (Ig)G4 and CCL26/eotaxin-3 are being evaluated [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Nonspecific laboratory abnormalities that may be observed in EGPA include [
         <a href="#rid6">
          6,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normochromic, normocytic anemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Leukocytosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum IgE is frequently elevated (75 percent) and may vary with the activity of the vasculitic process [
         <a href="#rid68">
          68
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypergammaglobulinemia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A positive rheumatoid factor or antinuclear antibody test at low titer
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal or elevated complement (C3, C4, CH50) levels
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiographs are typically obtained during a flare of asthma or to evaluate peripheral eosinophilia. Chest high resolution computed tomography (HRCT) is obtained to evaluate persistent or unexplained dyspnea, an abnormal chest radiograph, or gas transfer abnormalities, such as a low diffusion capacity or low pulse oximetry, and is more sensitive than a conventional radiograph. In a series of 15 patients with EGPA, HRCT identified lung disease in 5 patients with a normal chest radiograph [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chest radiograph
         </strong>
         – Chest radiographic abnormalities in patients with EGPA are diverse and include transient, patchy opacities (75 percent of patients) without lobar or segmental distribution, symmetrical opacities in an axillary and peripheral distribution, diffuse or miliary opacities, and bilateral nodular disease without cavitation  (
         <a class="graphic graphic_diagnosticimage graphicRef71677 graphicRef59884" href="/z/d/graphic/71677.html" rel="external">
          image 1A-B
         </a>
         ) [
         <a href="#rid70">
          70-73
         </a>
         ]. Pleural effusions are found in approximately 30 percent of patients and are usually exudative and eosinophilic [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HRCT
         </strong>
         – Typical HRCT findings in EGPA include patchy, non-fixed ground glass opacities and consolidations that are peripheral or randomly located [
         <a href="#rid69">
          69
         </a>
         ]. Pulmonary micronodules, interlobular septal thickening, bronchial wall thickening, bronchial dilation, and pleural fluid can also be seen. One series described parenchymal consolidation or ground glass opacification on the CT scans of 10 of 17 patients [
         <a href="#rid73">
          73
         </a>
         ]. These findings are not specific for EGPA, but may guide choice of a location for bronchoalveolar lavage or lung biopsy and help in the assessment of the extent of disease. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A less common HRCT feature is a significant enlargement of the peripheral pulmonary arteries (when compared to the corresponding bronchi) in combination with a stellate and irregular configuration of some pulmonary arteries (referred to as the vasculitis sign)  (
         <a class="graphic graphic_diagnosticimage graphicRef73909" href="/z/d/graphic/73909.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sinus CT
         </strong>
         – Sinus CT features include thickening of sinus and nasal mucosa, nasal polyps, and absence of bony erosion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac magnetic resonance imaging (MRI)
         </strong>
         – Cardiac MRI is discussed below. (See
         <a class="local">
          'Cardiovascular tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spirometry typically shows variable airflow limitation (obstruction) consistent with asthma [
         <a href="#rid10">
          10
         </a>
         ]. Some patients may have a component of irreversible airflow limitation noted on spirometry or peak expiratory flow. When lung parenchymal involvement occurs, lung volume measurements (eg, total vital capacity and forced vital capacity) may be decreased. In addition, gas transfer abnormalities may be manifest by a low pulse oximetry at rest or with exertion, or by a decrease in the diffusion capacity. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/569.html" rel="external">
          "Pulmonary function testing in asthma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoalveolar lavage (BAL) is typically performed in patients with interstitial opacities on radiographic imaging to evaluate for eosinophilia, infection, alveolar hemorrhage, or malignancy. In EGPA, BAL fluid typically has a high percentage of eosinophils (usually greater than 30 percent) [
         <a href="#rid74">
          74,75
         </a>
         ]. However, this finding is not specific for EGPA and would only be present in a patient with active pneumonitis  (
         <a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic confirmation of EGPA is desirable, but not always possible. The biopsy site is selected from among the least invasive options (eg, skin, kidney, peripheral nerve, lacrimal gland, conjunctival) that is most likely to yield a diagnosis. As an example, when either skin disease or peripheral neuropathy is present, biopsy of one of these less invasive sites is often preferred to a lung biopsy. In one study, 15 of 28 patients with a peripheral neuropathy and EGPA had evidence of a necrotizing vasculitis on a peripheral nerve biopsy [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Nasal cytology demonstrates eosinophilia in approximately 60 percent of patients with chronic rhinosinusitis due to EGPA [
         <a href="#rid21">
          21
         </a>
         ], which can be supportive but not diagnostic. In a series that included 23 patients who underwent nasal or sinus mucosal biopsies, the sensitivity for EGPA was 35 percent [
         <a href="#rid8">
          8
         </a>
         ]. Sinus biopsy is generally obtained at the time of sinus surgery to relieve obstruction.
        </p>
        <p>
         Lung biopsy is reserved for situations where none of the extrapulmonary sites is appropriate for biopsy, the HRCT scan shows lung parenchyma involvement, and therapeutic decisions would be altered by the results. Lung biopsy is obtained from an area of HRCT abnormality. In general, thoracoscopic or open surgical biopsy is preferred over transbronchial lung biopsy, which does not provide a sufficient sample size. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         The lung histopathology in EGPA may show asthmatic bronchitis, eosinophilic pneumonia, extravascular granulomas, or vasculitis (affecting arteries, veins, or capillaries). The histopathologic findings of EGPA are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Cardiovascular tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically obtain serum levels of NT-proBNP and cardiac troponin, an electrocardiogram, and a transthoracic echocardiogram (looking for wall motion abnormalities, mural thrombi, and valvular thrombi) as part of the initial evaluation of a patient with a diagnosis of EGPA even in the absence of symptoms suggesting cardiac disease [
         <a href="#rid31">
          31,59,76,77
         </a>
         ]. The rationale for this routine testing is that cardiac involvement is the leading cause of mortality due to EGPA, and approximately 40 percent of asymptomatic patients with a normal ECG have evidence of cardiac involvement with EGPA on echocardiogram [
         <a href="#rid8">
          8,29,31
         </a>
         ]. We use this initial testing to guide further imaging and decisions about endomyocardial biopsy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transthoracic echocardiogram
         </strong>
         – The most common echocardiographic finding in EGPA is wall motion abnormalities, which were found in 41 percent of patients in one case series [
         <a href="#rid31">
          31
         </a>
         ]. Other findings include valvular abnormalities (eg, mitral or aortic regurgitation), pericardial effusion, mural thrombi, and pulmonary hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular magnetic resonance imaging (CMR)
         </strong>
         – If abnormalities are noted on ECG or echocardiogram, we perform CMR with gadolinium enhancement, if renal function is adequate [
         <a href="#rid78">
          78
         </a>
         ]. Gadolinium should be used with caution in patients with acute kidney injury or advanced renal insufficiency (eg, estimated glomerular filtration rate [eGFR] &lt;30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         ), because of the risk of inducing nephrogenic systemic fibrosis. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Gadolinium enhancement on CMR has been reported to correlate with endomyocardial biopsy evidence of eosinophilic infiltration [
         <a href="#rid79">
          79
         </a>
         ]. Assessment of late images may reveal myocardial necrosis or fibrosis [
         <a href="#rid34">
          34,80
         </a>
         ]. CMR may be a useful tool for EGPA risk stratification and treatment individualization [
         <a href="#rid81">
          81,82
         </a>
         ], although additional testing may be needed to differentiate active disease from fibrosis [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The exact sensitivity and specificity of CMR for myocardial involvement with EGPA is not known. A comparison of echocardiography and CMR in a small group of patients found that echocardiography had a sensitivity and specificity of 83 and 80 percent, respectively, for abnormalities on CMR, while CMR had a sensitivity and specificity of 88 and 72 percent, respectively, for echocardiographic abnormalities [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fluoro-2-deoxyglucose-positron emission tomography (FDG-PET)
         </strong>
         – FDG-PET has been evaluated as a method to determine whether delayed myocardial enhancement on CMR is due to fibrosis or inflammation. Among 14 patients with EGPA in remission and delayed myocardial enhancement on CMR, FDG-PET uptake was reduced in 10, increased in 2, and normal in 2 [
         <a href="#rid78">
          78
         </a>
         ]. FDG-PET uptake was also normal in six patients with normal CMR findings. As this study evaluated a small number of patients and the outcomes of alterations in therapy based on FDG-PET results were not assessed, further study is needed to determine the most appropriate role for FDG-PET in the evaluation of EGPA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endomyocardial biopsy
         </strong>
         – An endomyocardial biopsy is performed selectively when EGPA is suspected, the noninvasive testing suggests endomyocarditis,
         <strong>
          and
         </strong>
         the documentation of cardiac involvement would affect the decision about whether to initiate immunosuppressive therapy. (See
         <a class="medical medical_review" href="/z/d/html/4923.html" rel="external">
          "Endomyocardial biopsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          DIAGNOSTIC CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of different sets of criteria for the diagnosis of EGPA have been proposed [
         <a href="#rid7">
          7,10,54,64
         </a>
         ]. The classifications used most commonly are the American College of Rheumatology (ACR, preferred) and the Lanham criteria [
         <a href="#rid10">
          10,54
         </a>
         ]. Revised criteria from the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) and ACR have been developed for use in clinical trials but not for diagnosis [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults", section on 'Classification criteria'
         </a>
         .)
        </p>
        <p>
         In 1990, the ACR established six criteria for the classification of EGPA in a patient with documented vasculitis [
         <a href="#rid54">
          54
         </a>
         ]. The presence of four or more of these criteria had a sensitivity of 85 percent and a specificity of 99.7 percent for EGPA:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asthma (a history of wheezing or the finding of diffuse high pitched wheezes on expiration)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Greater than 10 percent eosinophils on the differential leukocyte count
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mononeuropathy (including multiplex) or polyneuropathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Migratory or transient pulmonary opacities detected radiographically
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paranasal sinus abnormality
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biopsy containing a blood vessel showing the accumulation of eosinophils in extravascular areas  (
         <a class="graphic graphic_picture graphicRef57180 graphicRef82366" href="/z/d/graphic/57180.html" rel="external">
          picture 3A-B
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The Lanham criteria include asthma, peak peripheral blood eosinophilia in excess of 1500 cells/microL, and systemic vasculitis involving two or more extra-pulmonary organs [
         <a href="#rid10">
          10
         </a>
         ]. In this classification, all three criteria must be met for a diagnosis of EGPA.
        </p>
        <p>
         A question that arises in the categorization of patients with suspected EGPA is how to classify patients with asthma and blood eosinophilia &gt;1500 cells/microL and/or ≥10 percent of leukocytes, but without definite evidence of vasculitis outside the lungs, nose, and sinuses. One proposal is to reserve the designation of EGPA for patients with asthma and blood eosinophils ≥1500 cells/microL (1.5 G/L) and/or ≥10 percent of leukocytes
         <strong>
          and
         </strong>
         one or more of the following [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Definite polyangiitis: Biopsy showing necrotizing vasculitis, biopsy showing necrotizing or crescentic glomerulonephritis, alveolar hemorrhage, palpable purpura, or myocardial infarction due to proven coronaritis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Definite surrogates for vasculitis: Hematuria associated with red cell casts or &gt;10 percent dysmorphic erythrocytes; hematuria with 2+ proteinuria; leukocytoclastic vasculitis/eosinophilic infiltration of an arterial wall on biopsy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mononeuritis or mononeuritis multiplex
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antineutrophil cytoplasmic antibody (ANCA) and systemic manifestations (eg, myocarditis, pericarditis, peripheral neuropathy, other renal disease, abdominal pain)
        </p>
        <p>
        </p>
        <p>
         This proposal suggests creating a new category called “hypereosinophilic asthma with systemic manifestations” for patients with asthma, hypereosinophilia (≥1500 cells/microL and/or ≥10 percent of leukocytes), and any systemic manifestation, but
         <strong>
          without
         </strong>
         ANCA, definite polyangiitis, a surrogate of polyangiitis, or mononeuritis.
        </p>
        <p class="headingAnchor" id="H1498462089">
         <span class="h1">
          DIAGNOSIS AND POSTDIAGNOSTIC TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         In practice, the diagnosis of EGPA is based on a combination of eosinophilia (≥1500 cells/microL), asthma, rhinosinusitis, and histopathology from the lung or other affected tissues (eg, skin, peripheral nerve, gastrointestinal tract) showing eosinophilic infiltration with or without vasculitis (see
         <a class="local">
          'Diagnostic criteria'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Pathology'
         </a>
         ). Alternatively, after excluding processes in the differential diagnosis, a presumptive diagnosis of EGPA can be made in patients with these clinical features and peripheral eosinophilia when histopathology is not available. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Once EGPA has been diagnosed, patients should be evaluated for possible kidney, heart, gastrointestinal, or peripheral nerve involvement (if not already performed), as these are associated with a poor prognosis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal involvement is assessed with urinalysis (eg, hematuria, proteinuria, red blood cell casts), blood urea nitrogen, serum creatinine. The antineutrophil cytoplasmic antibody (ANCA) is almost always positive in patients with glomerulonephritis due to EGPA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial cardiovascular testing typically includes serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin, an electrocardiogram, and possibly a transthoracic echocardiogram [
         <a href="#rid84">
          84
         </a>
         ]. Further testing is based on the results of these tests and is described above. (See
         <a class="local">
          'Cardiovascular tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for gastrointestinal involvement is guided by the specific symptoms (eg, upper abdominal pain, diarrhea, hematochezia), but may include upper or lower endoscopy with biopsy. Patients with ascites should have the fluid sampled. (See
         <a class="local">
          'Renal'
         </a>
         above and
         <a class="local">
          'Cardiovascular'
         </a>
         above and
         <a class="local">
          'Gastrointestinal tract'
         </a>
         above and
         <a class="local">
          'Neurologic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral nerve involvement is evaluated with a focused history and physical examination, followed, as indicated, by nerve conduction studies, and electromyogram (NCS/EMG). Biopsy is generally not needed in a patient with a known systemic vasculitis like EGPA. (See
         <a class="local">
          'Neurologic'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main diseases to consider in the differential diagnosis of EGPA are aspirin-exacerbated respiratory disease (AERD), the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis (GPA), and microscopic polyangiitis. The following observations may help to narrow the differential diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspirin-exacerbated respiratory disease
         </strong>
         – AERD refers to the combination of asthma, chronic rhinosinusitis with nasal polyposis, and reactions to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (acetylsalicylic acid [ASA]) and other COX-1 inhibiting nonsteroidal antiinflammatory drugs (NSAIDs) characterized by bronchoconstriction, nasal congestion, and rhinorrhea. These patients may also have eosinophilia, but do not have eosinophilic pneumonia or the other organ system involvement seen in EGPA. However, AERD may evolve into EGPA [
         <a href="#rid85">
          85
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/520.html" rel="external">
          "Aspirin-exacerbated respiratory disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic eosinophilic pneumonia
         </strong>
         – Chronic eosinophilic pneumonia usually lacks granulomas on biopsy and generally does not involve organs other than the lung [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Occasionally, an episode of eosinophilic pneumonia may precede the other manifestations of EGPA, making it difficult to differentiate EGPA from chronic eosinophilic pneumonia. These patients are monitored closely for development of evidence of additional organ involvement that would secure the diagnosis of EGPA. (See
         <a class="local">
          'Phases of disease'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia", section on 'Chronic eosinophilic pneumonia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Allergic bronchopulmonary aspergillosis
         </strong>
         – Allergic bronchopulmonary aspergillosis is another cause of asthma, radiographic pulmonary opacities, and eosinophilia, but does not affect extrapulmonary organs other than the nose and sinuses. (See
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypereosinophilic syndrome
         </strong>
         – While some patients with the hypereosinophilic syndrome (HES) may have a cough, a minority have pulmonary opacities, and asthma is rare. When a clear differentiation cannot be made on clinical grounds, molecular testing for the FIP1L1/PDGFRalpha mutation may be helpful as this mutation is suggestive of HES. (See
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'Hematologic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other vasculitides
         </strong>
         – Granulomatosis with polyangiitis, microscopic polyangiitis, and EGPA can all affect the lung, although the degree of eosinophilia and presence of asthma are typical of EGPA and not usually seen in the other two. The type of ANCA seen in EGPA is more typically anti-myeloperoxidase, whereas in granulomatosis with polyangiitis it is more likely anti-proteinase 3. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other eosinophilic diseases
         </strong>
         – Drug-induced eosinophilia  (
         <a class="graphic graphic_table graphicRef84015" href="/z/d/graphic/84015.html" rel="external">
          table 3
         </a>
         ), toxocariasis, strongyloidiasis, human immunodeficiency virus (HIV) infection, and paraneoplastic eosinophilia are in the differential diagnosis of EGPA [
         <a href="#rid59">
          59
         </a>
         ]. Depending on the patient’s travel, residence, and exposure history and symptom pattern, serologic testing for
         <em>
          Toxocara
         </em>
         and
         <em>
          Strongyloides
         </em>
         and/or empiric treatment, testing for HIV infection, serum B12, and serum tryptase levels may be appropriate. (See
         <a class="medical medical_review" href="/z/d/html/5691.html" rel="external">
          "Approach to the patient with unexplained eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/100544.html" rel="external">
          "Eosinophil biology and causes of eosinophilia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5716.html" rel="external">
          "Toxocariasis: Visceral and ocular larva migrans"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3736106388">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">
          "Society guideline links: Vasculitis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was formerly called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by chronic rhinosinusitis, asthma, and prominent peripheral blood eosinophilia (≥ 1500 cells/microL and/or &gt;10 percent eosinophils on differential leukocyte count). The exact etiology of EGPA is unknown. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Asthma is the cardinal feature of EGPA (occurring in more than 95 percent of patients) and usually precedes the vasculitic phase by approximately 8 to 10 years. (See
         <a class="local">
          'Asthma and lung disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ear, nose, and throat involvement, including serous otitis media, allergic rhinitis, nasal obstruction, recurrent sinusitis, and nasal polyposis, is reported in 70 to 85 percent patients with EGPA. (See
         <a class="local">
          'Upper airway and ear disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A peripheral neuropathy, usually mononeuritis multiplex, is seen in up to 75 percent of patients with EGPA. Central nervous system manifestations may include subarachnoid and cerebral hemorrhage, cerebral infarction, cranial nerve palsies, and loss of visual acuity. (See
         <a class="local">
          'Neurologic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two-thirds of EGPA patients have skin involvement; findings include palpable purpura, subcutaneous nodules, and macular or papular erythematous rashes. Skin biopsy is often helpful for confirming the diagnosis. (See
         <a class="local">
          'Skin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiac involvement is one of the more serious manifestations of EGPA, accounting for approximately one-half of deaths attributable to EGPA. It should be suspected in the presence of refractory dyspnea, clinical evidence of heart failure, or cardiac rhythm abnormalities, but can also be asymptomatic. (See
         <a class="local">
          'Cardiovascular'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blood eosinophilia
         </strong>
         – Most patients with EGPA have blood eosinophilia (typically above 1500/microL, often 5000 to 9000/microL), although this may be obscured by use of systemic glucocorticoids to control asthma. (See
         <a class="local">
          'Eosinophilia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antineutrophil cytoplasmic antibodies (ANCAs)
         </strong>
         – ANCAs are noted in 30 to 60 percent of EGPA patients. The majority of ANCAs associated with EGPA are directed against myeloperoxidase with a perinuclear staining pattern (called MPO-ANCA or P-ANCA). (See
         <a class="local">
          'Antineutrophil cytoplasmic antibodies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         – Typical findings on chest high resolution computed tomography (HRCT) include patchy parenchymal consolidation or ground glass opacification; nodules may also be noted. (See
         <a class="local">
          'Imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bronchoalveolar lavage
         </strong>
         – Bronchoalveolar lavage (BAL) fluid from patients with EGPA typically has a high percentage of eosinophils (usually greater than 30 percent), although this is a nonspecific finding  (
         <a class="graphic graphic_table graphicRef64886" href="/z/d/graphic/64886.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Bronchoalveolar lavage'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of EGPA is suggested by the combination of asthma, rhinosinusitis, and blood eosinophilia (≥1500 cells/microL), but should be confirmed by biopsy whenever possible. The biopsy site is selected from among the least invasive options (eg, skin, kidney, peripheral nerve, lacrimal gland, conjunctival) that is most likely to yield a diagnosis. Lung biopsy is reserved for situations where none of the extrapulmonary sites is appropriate for biopsy and the HRCT shows lung parenchyma involvement. (See
         <a class="local">
          'Biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once EGPA has been diagnosed, patients should be evaluated for possible kidney, heart, gastrointestinal, or peripheral nerve involvement (if not already assessed), as these are associated with a poor prognosis. (See
         <a class="local">
          'Diagnosis and postdiagnostic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         – Two sets of diagnostic criteria are commonly used; the American College of Rheumatology (ACR) criteria for the classification of EGPA in a patient with documented vasculitis and the Lanham criteria. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The main diseases to consider in the differential diagnosis of EGPA are aspirin-exacerbated respiratory disease, the eosinophilic pneumonias, allergic bronchopulmonary aspergillosis, the hypereosinophilic syndrome, granulomatosis with polyangiitis, and microscopic polyangiitis. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           CHURG J, STRAUSS L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Churg A. Pulmonary angiitis and granulomatosis revisited. Hum Pathol 1983; 14:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 2017; 16:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnoux C, Guillevin L. Churg-Strauss syndrome: evidence for disease subtypes? Curr Opin Rheumatol 2010; 22:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berti A, Cornec D, Casal Moura M, et al. Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors of Long-term Asthma Severity. Chest 2020; 157:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Churg A, Brallas M, Cronin SR, Churg J. Formes frustes of Churg-Strauss syndrome. Chest 1995; 108:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun 2014; 48-49:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chumbley LC, Harrison EG Jr, DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977; 52:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in Churg-Strauss syndrome. Laryngoscope 2008; 118:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srouji I, Lund V, Andrews P, Edwards C. Rhinologic symptoms and quality-of-life in patients with Churg-Strauss syndrome vasculitis. Am J Rhinol 2008; 22:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seccia V, Baldini C, Latorre M, et al. Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. Int Arch Allergy Immunol 2018; 175:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Low CM, Keogh KA, Saba ES, et al. Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies. Int Forum Allergy Rhinol 2020; 10:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope 2001; 111:1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamaru Y, Takagi D, Suzuki M, et al. Otologic and Rhinologic Manifestations of Eosinophilic Granulomatosis with Polyangiitis. Audiol Neurootol 2016; 21:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RA, Churg J. Churg-Strauss syndrome. Br J Dermatol 1992; 127:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bridges C, Shenk MER, Martin K, Launhardt A. Cutaneous manifestations of childhood Eosinophilic Granulomatosis with Polyangiitis (cEGPA): A case-based review. Pediatr Dermatol 2020; 37:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otsuka T, Iwata H, Kosumi H, et al. Refractory oral ulcers in eosinophilic granulomatosis with polyangiitis. J Dermatol 2019; 46:e377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawakami T, Soma Y, Kawasaki K, et al. Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome. Arch Dermatol 2005; 141:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature. Clin Rheumatol 2009; 28:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dennert RM, van Paassen P, Schalla S, et al. Cardiac involvement in Churg-Strauss syndrome. Arthritis Rheum 2010; 62:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis 2013; 72:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta AK, Langford CA, Taylor DO, et al. A 39-Year-Old Postpartum Woman With Foot Drop and Shortness of Breath. Chest 2016; 149:e61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczeklik W, Miszalski-Jamka T, Mastalerz L, et al. Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission. Circ J 2011; 75:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Della Rossa A, Baldini C, Tavoni A, et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002; 41:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solans R, Bosch JA, Pérez-Bocanegra C, et al. Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. Rheumatology (Oxford) 2001; 40:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolf J, Bergner R, Mutallib S, et al. Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study. Eur J Neurol 2010; 17:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos-Pinheiro F, Li Y. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting with polyneuropathy--a case series. J Clin Neuromuscul Dis 2015; 16:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho HJ, Yune S, Seok JM, et al. Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center. J Clin Neurol 2017; 13:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabio JM, Rivero-Rodriguez M, Vargas-Hitos JA. Demographic and Clinical Characteristics Associated with Central Nervous System Hemorrhage in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Case Report and Review of the Literature. J Rheumatol 2017; 44:1413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain 1999; 122 ( Pt 3):427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liou HH, Liu HM, Chiang IP, et al. Churg-Strauss syndrome presented as multiple intracerebral hemorrhage. Lupus 1997; 6:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheerin UM, Barreto J, Brown MM, et al. Subarachnoid haemorrhage as the first clinical manifestation of Churg-Strauss syndrome. J Neurol 2008; 255:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André R, Cottin V, Saraux JL, et al. Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. Autoimmun Rev 2017; 16:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akella SS, Schlachter DM, Black EH, Barmettler A. Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature. Ophthalmic Plast Reconstr Surg 2019; 35:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Am J Kidney Dis 2006; 47:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kronbichler A, Shin JI, Lee KH, et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev 2020; 19:102495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parent ME, Larue S, Ellezam B. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting as diffuse myositis. BMC Musculoskelet Disord 2014; 15:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koppikar S, Al-Dabie G, Jerome D, Vinik O. Eosinophilic granulomatosis with polyangiitis presenting with myositis: case based review. Rheumatol Int 2020; 40:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Churg A. Recent advances in the diagnosis of Churg-Strauss syndrome. Mod Pathol 2001; 14:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sidhu B, Nanda U, Abbas S. Is this an exacerbation of asthma? A cautionary tale. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAleavey N, Millar A, Pendleton A. Cardiac involvement as the main presenting feature in eosinophilic granulomatosis with polyangiitis. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hara T, Yamaguchi K, Iwase T, et al. Eosinophilic myocarditis due to Churg-Strauss syndrome with markedly elevated eosinophil cationic protein. Int Heart J 2013; 54:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kakouros N, Bastiaenen R, Kourliouros A, Anderson L. Churg-Strauss presenting as acute coronary syndrome: sometimes it's zebras. BMJ Case Rep 2011; 2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitt WH, Csernok E, Kobayashi S, et al. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage. Arthritis Rheum 1998; 41:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid AJ, Harrison BD, Watts RA, et al. Churg-Strauss syndrome in a district hospital. QJM 1998; 91:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sablé-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nathani N, Little MA, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52:2926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papo M, Sinico RA, Teixeira V, et al. Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology (Oxford) 2021; 60:4355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahn SS, Song JJ, Park YB, Lee SW. Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis. Korean J Intern Med 2022; 37:1241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu EY, Hernandez ML, Jennette JC, Falk RJ. Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review. J Allergy Clin Immunol Pract 2018; 6:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczeklik W, Sokołowska B, Mastalerz L, et al. Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis. Clin Rheumatol 2010; 29:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi YH, Im JG, Han BK, et al. Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings. Chest 2000; 117:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erzurum SC, Underwood GA, Hamilos DL, Waldron JA. Pleural effusion in Churg-Strauss syndrome. Chest 1989; 95:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buschman DL, Waldron JA Jr, King TE Jr. Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings. Am Rev Respir Dis 1990; 142:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worthy SA, Müller NL, Hansell DM, Flower CD. Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients. AJR Am J Roentgenol 1998; 170:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J 2016; 48:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sevim T, Aksoy E, Akyıl FT, et al. Eosinophilic Lung Disease: Accompanied with 12 Cases. Turk Thorac J 2015; 16:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sauvetre G, Fares J, Caudron J, et al. [Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review]. Rev Med Interne 2010; 31:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmursztejn J, Vignaux O, Cohen P, et al. Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients. Clin Exp Rheumatol 2009; 27:S70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marmursztejn J, Guillevin L, Trebossen R, et al. Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients. Rheumatology (Oxford) 2013; 52:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccouche H, Yilmaz A, Alscher D, et al. Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome. Circulation 2008; 117:1745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mavrogeni S, Manoussakis MN, Karagiorga TC, et al. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides. Arthritis Rheum 2009; 61:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mavrogeni S, Karabela G, Gialafos E, et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance. Inflamm Allergy Drug Targets 2013; 12:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miszalski-Jamka T, Szczeklik W, Sokołowska B, et al. Standard and feature tracking magnetic resonance evidence of myocardial involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegener's) in patients with normal electrocardiograms and transthoracic echocardiography. Int J Cardiovasc Imaging 2013; 29:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 2022; 81:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Care Res (Hoboken) 2021; 73:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ameratunga R, Steele R. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss vasculitis) presenting as Samter's triad. J Allergy Clin Immunol Pract 2018; 6:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hueto-Perez-de-Heredia JJ, Dominguez-del-Valle FJ, Garcia E, et al. Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome. Eur Respir J 1994; 7:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinfeld S, Golstein M, De Vuyst P. Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS). Eur Respir J 1994; 7:2098.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4347 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14819261" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Allergic granulomatosis, allergic angiitis, and periarteritis nodosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6352458" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary angiitis and granulomatosis revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19508943" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Churg-Strauss angiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143092" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16612766" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9990352" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23045170" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23044708" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27671089" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6366453" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19851111" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Churg-Strauss syndrome: evidence for disease subtypes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19154547" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31958440" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors of Long-term Asthma Severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9466639" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634860" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Formes frustes of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24530234" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18640" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17989571" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nasal polyposis in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16698700" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Ear, nose and throat manifestations of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18702907" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rhinologic symptoms and quality-of-life in patients with Churg-Strauss syndrome vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29393242" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31793227" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis: clinical presentation and antineutrophil cytoplasmic antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568616" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Otological manifestations of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26812614" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Otologic and Rhinologic Manifestations of Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1390162" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32212191" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cutaneous manifestations of childhood Eosinophilic Granulomatosis with Polyangiitis (cEGPA): A case-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31050016" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Refractory oral ulcers in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16027304" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Initial cutaneous manifestations consistent with mononeuropathy multiplex in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593229" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19238502" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Postpartum Churg-Strauss syndrome with severe cardiac involvement: description of a case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20112390" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cardiac involvement in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22887848" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26867857" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A 39-Year-Old Postpartum Woman With Foot Drop and Shortness of Breath.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21139253" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Multimodality assessment of cardiac involvement in Churg-Strauss syndrome patients in clinical remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19015208" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12422002" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11477281" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20050889" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Neurologic complications of Churg-Strauss syndrome--a prospective monocentric study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25695917" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting with polyneuropathy--a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28079316" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28864668" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Demographic and Clinical Characteristics Associated with Central Nervous System Hemorrhage in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10094252" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinicopathological features of Churg-Strauss syndrome-associated neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9104737" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Churg-Strauss syndrome presented as multiple intracerebral hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18350356" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Subarachnoid haemorrhage as the first clinical manifestation of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28709761" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30134390" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ophthalmic Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome): A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113641" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Renal involvement in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16632015" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renal involvement in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32068190" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinical associations of renal involvement in ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25414144" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) presenting as diffuse myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32270295" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Eosinophilic granulomatosis with polyangiitis presenting with myositis: case based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11743052" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Recent advances in the diagnosis of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12598156" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2202307" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24072836" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Is this an exacerbation of asthma? A cautionary tale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23853013" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Cardiac involvement as the main presenting feature in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23428926" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Eosinophilic myocarditis due to Churg-Strauss syndrome with markedly elevated eosinophil cationic protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22700996" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Churg-Strauss presenting as acute coronary syndrome: sometimes it's zebras.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25971154" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506572" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9604074" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Churg-Strauss syndrome in a district hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263885" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18492740" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12967693" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16142760" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33347592" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34883552" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30197069" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Eosinophilic Granulomatosis with Polyangiitis: Clinical Pathology Conference and Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20623310" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pulmonary findings in Churg-Strauss syndrome in chest X-rays and high resolution computed tomography at the time of initial diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10631208" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Thoracic manifestation of Churg-Strauss syndrome: radiologic and clinical findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2721280" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pleural effusion in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2382908" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Churg-Strauss pulmonary vasculitis. High-resolution computed tomography scanning and pathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9456932" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Churg-Strauss syndrome: the spectrum of pulmonary CT findings in 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27587545" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29404099" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Eosinophilic Lung Disease: Accompanied with 12 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20605285" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : [Usefulness of magnetic resonance imaging in Churg-Strauss syndrome related cardiac involvement. A case series of three patients and literature review].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19646350" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Impact of cardiac magnetic resonance imaging for assessment of Churg-Strauss syndrome: a cross-sectional study in 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22772324" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography: a prospective study on 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378628" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Images in cardiovascular medicine. Magnetic resonance assessment and therapy monitoring of cardiac involvement in Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644909" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23909889" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23212274" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Standard and feature tracking magnetic resonance evidence of myocardial involvement in Churg-Strauss syndrome and granulomatosis with polyangiitis (Wegener's) in patients with normal electrocardiograms and transthoracic echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35110334" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34235880" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28847652" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss vasculitis) presenting as Samter's triad.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8050532" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Chronic eosinophilic pneumonia as a presenting feature of Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7875290" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Chronic eosinophilic pneumonia (CEP) as a presenting feature of Churg-Strauss syndrome (CSS).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
